Cardiac Rehabilitation. The Evidence-Based Program Most Patients Never Attend.

Cardiac rehabilitation is among the most evidence-based interventions in cardiovascular medicine, with a mortality benefit that rivals the major medications prescribed after a cardiac event. A 2016 Cochrane meta-analysis of 63 randomized trials covering 14,486 patients with coronary heart disease found that exercise-based cardiac rehabilitation reduced cardiovascular mortality by 26 percent and all-cause mortality by 20 percent. 5 / Solid Despite this evidence, participation rates in cardiac rehabilitation remain below 30 percent of eligible patients in the United States. Most eligible patients are either not referred by their treating physicians, are referred but do not enroll, or start the program and do not complete it.

This gap between the evidence and the participation rate is not a mystery about patient motivation. It is a failure of clinical delivery, referral practice, and patient education at the point of discharge.

The Mechanism

Cardiac rehabilitation works through several simultaneous biological pathways, and the cumulative effect of those pathways operating together for 12 weeks is what produces the mortality benefit. No single mechanism fully explains the outcome data; the program is effective because it addresses multiple physiological impairments at once. 5 / Solid

Endothelial function. Aerobic exercise training is one of the most potent physiological stimuli for improving endothelial function. The endothelium, the single-cell lining of every blood vessel, produces nitric oxide in response to shear stress from blood flow. Nitric oxide causes vasodilation, inhibits platelet aggregation, reduces oxidative stress, and suppresses inflammatory signaling in the vessel wall. In patients with coronary artery disease, endothelial function is impaired at baseline. Repeated aerobic exercise sessions improve nitric oxide bioavailability within weeks and the improvement is detectable by non-invasive measures of flow-mediated dilation.

Autonomic rebalancing. The post-cardiac event period is characterized by elevated sympathetic tone, reflected in an elevated resting heart rate and depressed heart rate variability (HRV). This sympathetic dominance is independently associated with worse outcomes after MI. Aerobic exercise conditioning increases vagal (parasympathetic) tone, lowering resting heart rate and improving HRV. The resting heart rate reduction seen with cardiac rehabilitation is clinically meaningful: patients who complete the program typically achieve resting heart rate reductions of 5 to 10 beats per minute. For a post-MI patient at an initial resting heart rate of 85 beats per minute, reducing to 75 through exercise conditioning translates to approximately 5 million fewer heartbeats per year, with corresponding reductions in myocardial oxygen demand.

Inflammatory load reduction. Post-cardiac event inflammation is sustained and contributes to atherosclerotic progression. Supervised exercise training reduces high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and other inflammatory biomarkers over the course of a rehabilitation program. The STABILITY trial and related analyses have documented that elevated hsCRP in post-MI patients predicts recurrent events independently of LDL cholesterol. Reducing inflammatory load through exercise adds to the anti-inflammatory effects of statins and represents a complementary mechanism, not a redundant one.

Metabolic adaptation. Aerobic exercise training improves insulin sensitivity, which matters substantially in a post-cardiac event population where insulin resistance and type 2 diabetes are common comorbidities. Improved insulin sensitivity reduces triglyceride production, raises HDL cholesterol, improves glucose disposal, and reduces visceral adiposity over time. These metabolic adaptations are additive to the effects of medications.

Cardiac contractile efficiency. In patients with reduced left ventricular ejection fraction, cardiac rehabilitation improves peak oxygen uptake (VO2 peak), a measure of cardiorespiratory fitness that is one of the strongest predictors of cardiovascular mortality in the post-event population. The improvement in VO2 peak reflects both peripheral adaptations (improved skeletal muscle oxygen extraction) and central adaptations (improved cardiac output at submaximal workloads). A 2019 meta-analysis by Taylor and colleagues in the Cochrane Database documented VO2 peak improvements of approximately 3.3 mL/kg/min across cardiac rehabilitation trials, which corresponds to a meaningful reduction in mortality risk given the well-established inverse relationship between cardiorespiratory fitness and cardiovascular death.

Depression treatment. Depression after a cardiac event is not a side effect of having had a serious illness. It is a biologically active state that independently worsens cardiovascular outcomes. Meta-analyses document that depression following MI is associated with a two- to three-fold increase in recurrent cardiac events and mortality. The mechanism involves elevated inflammatory cytokines, platelet hyperactivation, autonomic dysregulation, and reduced medication adherence in depressed patients. Cardiac rehabilitation addresses depression through structured activity, social interaction with peers in similar situations, and the psychological benefit of measurable physical progress. Programs that include formal psychosocial assessment and counseling show larger effects on mood outcomes than exercise-only protocols.

What the Evidence Shows

The Cochrane meta-analysis by Taylor and colleagues (2016) is the definitive aggregation of the clinical trial evidence. The 63 trials included in the analysis were heterogeneous in design, patient population, and program content, which strengthens the finding that the mortality benefit is robust across different program formats and patient types. The 26 percent reduction in cardiovascular mortality and 20 percent reduction in all-cause mortality were derived from the full trial population, including patients with coronary artery disease from multiple etiologies. 5 / Solid

For context on the magnitude of this effect: the ARR (absolute risk reduction) from high-intensity statin therapy in high-risk secondary prevention patients is approximately 1 to 2 percent per year for major cardiovascular events. The mortality benefit of cardiac rehabilitation in the Cochrane data is comparable to or exceeds the mortality benefit attributable to the major cardioprotective medications in the standard post-event regimen. Cardiac rehabilitation is not a lifestyle add-on. It is an intervention with a mortality effect size that belongs in the same conversation as statin therapy and beta-blockers.

Beyond the mortality data, the DANREHAB trial (Danish Cardiac Rehabilitation Trial), published by Zwisler and colleagues in the European Journal of Cardiovascular Prevention and Rehabilitation, documented that structured cardiac rehabilitation reduced re-hospitalization rates, improved quality of life scores, and was associated with better lipid control and blood pressure management at follow-up compared to usual care. The GOSPEL study (Long-Term Effects of a Multifactorial Intervention in Coronary Heart Disease), conducted in Italy and published in the Archives of Internal Medicine, found that extended cardiac rehabilitation with reinforcement sessions maintained cardiovascular event reduction over 3 years of follow-up, suggesting the benefit is durable when the program is well-designed.

In heart failure specifically, the HF-ACTION trial (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), published in JAMA in 2009 by O’Connor and colleagues, enrolled 2,331 patients with heart failure with reduced ejection fraction (HFrEF) and randomized them to exercise training or usual care. The primary composite endpoint (all-cause mortality or all-cause hospitalization) was reduced by 11 percent in the exercise group after adjustment for key prognostic factors. HF-ACTION confirmed cardiac rehabilitation’s role in the heart failure population and supported its coverage expansion by Medicare.

The referral gap problem has been quantified. A 2018 analysis published in the Journal of the American College of Cardiology by Menezes and colleagues documented that only 20 percent of MI patients and 10 percent of coronary artery bypass graft (CABG) patients who were eligible for cardiac rehabilitation actually enrolled in a program. Referral rates varied substantially by hospital, physician, geography, and insurance status. Women, older patients, and patients in rural areas were significantly less likely to be referred. The referral failure is the largest single contributor to the participation gap.

Why Patients Do Not Attend

The documented barriers to cardiac rehabilitation participation fall into several categories, each with a specific response.

Transportation is the most frequently cited barrier. Three sessions per week in a clinical facility for 12 weeks requires reliable access to a location that may not be close to home or work. The home-based cardiac rehabilitation model was developed specifically to address this, and the outcomes data supporting home-based programs are now sufficient that Medicare has expanded coverage to include them for eligible diagnoses.

Work obligations are the second most common barrier, particularly for men who return to work quickly after a cardiac event. Many programs offer early-morning or late-afternoon sessions to accommodate working patients. Some programs offer hybrid schedules that combine supervised in-facility sessions with home-based sessions in between. The scheduling barrier is solvable when the program is asked about it directly.

The belief that the program is not necessary is the third barrier, and the most dangerous. The man who had a stent placed, went home feeling better than before, and is now exercising on his own may genuinely not understand why a structured program would add anything. The answer is that self-directed exercise after a cardiac event does not provide cardiac monitoring during exertion, does not include the educational and risk factor management components, and does not address the post-event depression that is present in approximately 20 to 25 percent of patients and that independently predicts worse outcomes. The individual components of cardiac rehabilitation are each less effective than the combination.

Cost concerns exist despite the fact that cardiac rehabilitation is covered by Medicare for all approved indications and is covered by most private insurers. The coverage information is not consistently communicated at the time of referral, and patients who believe they will owe significant out-of-pocket costs may decline without investigating. Copays are typically modest, and many programs have financial assistance for patients with gaps in coverage.

Virtual Cardiac Rehabilitation

The pandemic accelerated adoption of home-based and telehealth cardiac rehabilitation models. Multiple randomized trials have documented that home-based programs with remote monitoring produce cardiovascular outcomes comparable to facility-based programs for appropriate patients. 4 / Promising The HOMCARE trial and the Home-HF study each documented equivalent improvements in VO2 peak, quality of life, and risk factor control between home-based and center-based protocols at 12-week follow-up.

The technology requirement for home-based programs is modest: a telemonitoring device that transmits heart rate and rhythm data to a supervising clinician, combined with structured exercise sessions delivered via video or app-based platform. The monitoring provides the safety oversight that supervised in-facility exercise provides, adapted for the home environment. Most patients who own a smartphone and have a reasonably safe home exercise environment are candidates for home-based programs.

If a facility-based cardiac rehabilitation program is not logistically feasible, the appropriate response is to ask specifically about home-based alternatives, not to accept the absence of any program.

Session Attendance and Dose-Response: Why Completing the Full Program Produces a Substantially Different Outcome

The question of whether it matters how many cardiac rehabilitation sessions a patient attends has been answered with enough statistical precision to change how the completion conversation should be framed. The data show not just that more sessions are associated with better outcomes, but that the relationship is dose-dependent in a way that makes completion a distinct clinical goal from enrollment.

Suaya and colleagues, publishing in Circulation in 2009, analyzed data from 601,099 Medicare beneficiaries eligible for cardiac rehabilitation and examined the relationship between the number of sessions attended and survival over four years. Patients who attended all 36 covered sessions had a 14 percent lower mortality rate than those who attended 1 to 24 sessions. Among patients who attended 25 or more sessions, the four-year mortality benefit was 14 to 19 percent greater than among partial attenders, after adjustment for age, sex, comorbidities, and procedure type. 5 / Solid

Hammill and colleagues, in a complementary Circulation study in 2010, found a stepwise reduction in mortality with increasing sessions attended in the same Medicare population. Each increment of sessions attended — 0 to 12, 13 to 24, 25 to 36 — was associated with a step-down in mortality rate, independent of diagnoses and comorbidities. The pattern was not linear in absolute terms: the gap between the lower attendance categories and high completion was disproportionately large, suggesting that the full program achieves physiological adaptations — particularly autonomic remodeling and sustainable fitness habits — that partial programs approach but do not fully establish.

The practical completion rate in the United States is sobering. Among patients who enroll in cardiac rehabilitation, studies consistently show that only 30 to 50 percent complete all covered sessions. The most common reasons for non-completion mirror those for non-enrollment: transportation, return to work, and the perception that early symptomatic improvement makes the remaining sessions unnecessary. This last reason is the most clinically problematic. The man who attends eight sessions, feels substantially better, and decides he has recovered does not understand that the mortality benefit the trial data document is associated with the full program, not with the early functional improvement. The symptomatic response in the first few weeks reflects cardiovascular adaptation that is still early in its course.

The attendance data also address a second question: is partial participation meaningfully better than none? The answer is clearly yes. Even attending one to twelve sessions is associated with better outcomes than zero enrollment. The Suaya data argue not for all-or-nothing but for maximizing attendance within logistical constraints. For a patient who can manage only two sessions per week due to work obligations, two sessions per week for 18 weeks produces the same session total as three sessions per week for 12 weeks, and that extended schedule is a legitimate clinical option to request from the program coordinator.

What to Do This Week

1. If you have had a cardiac event (myocardial infarction, coronary artery bypass surgery, stent placement, valve repair or replacement, or heart transplantation) and were not referred to cardiac rehabilitation, ask your cardiologist at your next visit for a formal referral. It is covered by Medicare and most private insurers for these indications. If your physician says you do not need it, ask specifically what the clinical reason is.

2. If you were referred and did not complete the program, ask about restarting. Programs routinely accept patients who need to restart, including those who stopped due to illness, logistical barriers, or loss of motivation. The evidence does not require completion at the original enrollment date. It requires completion.

3. If you have heart failure with reduced ejection fraction (HFrEF, typically defined as ejection fraction below 40 percent) and are not enrolled in a cardiac rehabilitation program, ask your cardiologist or heart failure specialist about eligibility. The HF-ACTION trial data support cardiac rehabilitation as one of the most evidence-based interventions available to this patient population.

4. If transportation or scheduling is the specific barrier that has prevented enrollment, ask about home-based cardiac rehabilitation programs. The outcomes data for home-based programs are strong enough that they are a genuine clinical option, not a lesser substitute.

5. If you are post-cardiac event and notice that your mood has been persistently low, that activities you previously found rewarding no longer interest you, or that you are more anxious or irritable than before, tell your cardiologist. Post-event depression is both common and clinically important. Cardiac rehabilitation addresses it directly. Pharmacological treatment for depression is also appropriate and effective in this population and does not conflict with cardiac rehabilitation participation.

The program is 12 weeks. The mortality benefit is documented. The barriers are real but mostly solvable. The absence of a referral is the single largest obstacle, and the solution to that one is to ask.